ATE326965T1 - Pharmazeutische zusammensetzung zur behandlung von autoimmunkrankheiten - Google Patents

Pharmazeutische zusammensetzung zur behandlung von autoimmunkrankheiten

Info

Publication number
ATE326965T1
ATE326965T1 AT96937258T AT96937258T ATE326965T1 AT E326965 T1 ATE326965 T1 AT E326965T1 AT 96937258 T AT96937258 T AT 96937258T AT 96937258 T AT96937258 T AT 96937258T AT E326965 T1 ATE326965 T1 AT E326965T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
pct
treatment
autoimmune diseases
date
Prior art date
Application number
AT96937258T
Other languages
English (en)
Inventor
Angelo Guglielmotti
Paolo Dionisio
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11372453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326965(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acraf filed Critical Acraf
Application granted granted Critical
Publication of ATE326965T1 publication Critical patent/ATE326965T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96937258T 1995-10-31 1996-10-26 Pharmazeutische zusammensetzung zur behandlung von autoimmunkrankheiten ATE326965T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95MI002242A IT1276031B1 (it) 1995-10-31 1995-10-31 Composizione farmaceutica per il trattamento delle malattie autoimmuni

Publications (1)

Publication Number Publication Date
ATE326965T1 true ATE326965T1 (de) 2006-06-15

Family

ID=11372453

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937258T ATE326965T1 (de) 1995-10-31 1996-10-26 Pharmazeutische zusammensetzung zur behandlung von autoimmunkrankheiten

Country Status (27)

Country Link
US (1) US6020356A (de)
EP (1) EP0858337B1 (de)
JP (1) JP4007615B2 (de)
KR (1) KR19990067237A (de)
CN (1) CN1229113C (de)
AT (1) ATE326965T1 (de)
AU (1) AU721841B2 (de)
BR (1) BR9611320B1 (de)
CA (1) CA2236256C (de)
CZ (1) CZ292258B6 (de)
DE (1) DE69636167T2 (de)
DK (1) DK0858337T3 (de)
EA (1) EA000826B1 (de)
ES (1) ES2264144T3 (de)
HK (1) HK1018219A1 (de)
HU (1) HU228051B1 (de)
IL (1) IL124291A (de)
IT (1) IT1276031B1 (de)
MX (1) MX9803478A (de)
NO (1) NO324130B1 (de)
NZ (1) NZ321580A (de)
PL (1) PL186377B1 (de)
PT (1) PT858337E (de)
SK (1) SK284069B6 (de)
TR (1) TR199800765T2 (de)
WO (1) WO1997016185A2 (de)
ZA (1) ZA969060B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
DK2049123T4 (en) 2006-08-03 2016-11-28 Horizon Pharma Ag LATE discharge-glucocorticoid treatment of rheumatoid ILLNESS
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EP2391369A1 (de) * 2009-01-26 2011-12-07 Nitec Pharma AG Glukokortikoid-behandlung von asthma mit verzögerter freisetzung
KR101736301B1 (ko) 2009-08-03 2017-05-29 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 1-벤질-3-하이드록시메틸-1ｈ-인다졸 및 이의 유도체 및 필요한 마그네슘 중간체들의 제조 방법
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015816A1 (en) * 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
WO1995004533A2 (en) * 1993-08-04 1995-02-16 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
WO1996035419A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
JP4007615B2 (ja) 2007-11-14
HUP9901303A3 (en) 2001-04-28
ITMI952242A1 (it) 1997-05-01
PT858337E (pt) 2006-09-29
ITMI952242A0 (de) 1995-10-31
HUP9901303A2 (hu) 1999-09-28
DE69636167D1 (de) 2006-06-29
CZ292258B6 (cs) 2003-08-13
US6020356A (en) 2000-02-01
CN1207042A (zh) 1999-02-03
KR19990067237A (ko) 1999-08-16
PL326371A1 (en) 1998-09-14
PL186377B1 (pl) 2003-12-31
DE69636167T2 (de) 2007-03-29
BR9611320B1 (pt) 2010-08-10
EA199800417A1 (ru) 1998-10-29
SK57998A3 (en) 1998-12-02
NO324130B1 (no) 2007-09-03
HU228051B1 (en) 2012-09-28
CA2236256C (en) 2005-02-22
AU721841B2 (en) 2000-07-13
CZ132698A3 (cs) 1998-10-14
DK0858337T3 (da) 2006-09-18
ES2264144T3 (es) 2006-12-16
WO1997016185A3 (en) 1997-07-03
CN1229113C (zh) 2005-11-30
AU7493896A (en) 1997-05-22
NO981951D0 (no) 1998-04-29
JPH11515020A (ja) 1999-12-21
EP0858337B1 (de) 2006-05-24
ZA969060B (en) 1997-05-29
NZ321580A (en) 2000-02-28
TR199800765T2 (xx) 1998-08-21
MX9803478A (es) 1998-11-30
NO981951L (no) 1998-06-29
SK284069B6 (sk) 2004-09-08
HK1018219A1 (en) 1999-12-17
EP0858337A2 (de) 1998-08-19
IL124291A (en) 2001-06-14
CA2236256A1 (en) 1997-05-09
EA000826B1 (ru) 2000-04-24
BR9611320A (pt) 1999-03-02
IT1276031B1 (it) 1997-10-24
WO1997016185A2 (en) 1997-05-09

Similar Documents

Publication Publication Date Title
NO995006D0 (no) Nye forbindelser
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
BG104620A (en) Oral pharmaceutical extended release dosage form
FI925342A (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
EP1210941A3 (de) Pharmazeutische Zusammensetzungen enthaltend Ritonavir (ABT-538) in Kombination mit Indinavir (MK-639) und deren Verwendung zur Behandlung von AIDS
ATE326965T1 (de) Pharmazeutische zusammensetzung zur behandlung von autoimmunkrankheiten
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
SE9502219D0 (sv) Novel medical use
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
WO1998038986A3 (en) Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0858337

Country of ref document: EP